|
US5665379A
(en)
|
1990-09-28 |
1997-09-09 |
Pharmacia & Upjohn Aktiebolag |
Lipid particle forming matrix, preparation and use thereof
|
|
MY115155A
(en)
|
1993-09-09 |
2003-04-30 |
Upjohn Co |
Substituted oxazine and thiazine oxazolidinone antimicrobials.
|
|
IL111004A
(en)
|
1993-09-30 |
1998-06-15 |
American Home Prod |
Oral formulations of rapamycin
|
|
US5536729A
(en)
|
1993-09-30 |
1996-07-16 |
American Home Products Corporation |
Rapamycin formulations for oral administration
|
|
JPH09510182A
(ja)
|
1993-11-17 |
1997-10-14 |
エルディーエス・テクノロジーズ・インコーポレーテッド |
カプセル封入されたドラッグデリバリー用透明液
|
|
US5759548A
(en)
|
1993-11-30 |
1998-06-02 |
Lxr Biotechnology Inc. |
Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
|
|
GB9405304D0
(en)
|
1994-03-16 |
1994-04-27 |
Scherer Ltd R P |
Delivery systems for hydrophobic drugs
|
|
US5538737A
(en)
|
1994-11-30 |
1996-07-23 |
Applied Analytical Industries, Inc. |
Oral compositions of H2 -antagonists
|
|
FR2736550B1
(fr)
|
1995-07-14 |
1998-07-24 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
|
|
US6277985B1
(en)
|
1995-09-15 |
2001-08-21 |
Pharmacia & Upjohn Company |
Aminoaryl oxazolidinone N-oxides
|
|
US6964946B1
(en)
|
1995-10-26 |
2005-11-15 |
Baker Norton Pharmaceuticals, Inc. |
Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
|
|
ATE239041T1
(de)
|
1996-02-09 |
2003-05-15 |
Basf Ag |
Humane antikörper welche an humanen tnfalpha binden
|
|
US5891469A
(en)
|
1997-04-02 |
1999-04-06 |
Pharmos Corporation |
Solid Coprecipitates for enhanced bioavailability of lipophilic substances
|
|
US20030220234A1
(en)
|
1998-11-02 |
2003-11-27 |
Selvaraj Naicker |
Deuterated cyclosporine analogs and their use as immunodulating agents
|
|
BE1011899A6
(fr)
|
1998-04-30 |
2000-02-01 |
Ucb Sa |
Compositions pharmaceutiques gelifiables utilisables.
|
|
ID26984A
(id)
|
1998-07-06 |
2001-02-22 |
Bristol Myers Squibb Co |
Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
|
|
US6267985B1
(en)
|
1999-06-30 |
2001-07-31 |
Lipocine Inc. |
Clear oil-containing pharmaceutical compositions
|
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
|
DE19913692A1
(de)
|
1999-03-25 |
2000-09-28 |
Basf Ag |
Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
|
|
DE19929361A1
(de)
|
1999-06-25 |
2001-01-04 |
Basf Ag |
Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
|
|
US20030236236A1
(en)
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
GB9918037D0
(en)
|
1999-07-30 |
1999-09-29 |
Biochemie Gmbh |
Organic compounds
|
|
ES2246922T3
(es)
|
1999-12-28 |
2006-03-01 |
Eisai Co., Ltd. |
Compuestos heterociclicos que tienen grupos de sulfonamida.
|
|
US20060183776A9
(en)
|
2000-03-03 |
2006-08-17 |
Eisai Co., Ltd. |
Liquid dosage formulations of donepezil
|
|
US6720338B2
(en)
|
2000-09-20 |
2004-04-13 |
Abbott Laboratories |
N-acylsulfonamide apoptosis promoters
|
|
US20020055631A1
(en)
|
2000-09-20 |
2002-05-09 |
Augeri David J. |
N-acylsulfonamide apoptosis promoters
|
|
UY26942A1
(es)
|
2000-09-20 |
2002-04-26 |
Abbott Lab |
N-acilsulfonamidas promotoras de la apoptosis
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
KR20030070150A
(ko)
|
2001-01-31 |
2003-08-27 |
화이자 프로덕츠 인크. |
Ｐｄｅ4 이소자임 억제제로서 유용한 에테르 유도체
|
|
US6927009B2
(en)
|
2001-05-22 |
2005-08-09 |
Fuji Photo Film Co., Ltd. |
Positive photosensitive composition
|
|
SK14642003A3
(sk)
|
2001-06-06 |
2004-12-01 |
Eli Lilly And Company |
Benzoylsulfónamidy a sulfonylbenzamidíny ako protinádorové činidlá
|
|
GB0123400D0
(en)
|
2001-09-28 |
2001-11-21 |
Novartis Ag |
Organic compounds
|
|
PT1471887E
(pt)
|
2002-02-04 |
2010-07-16 |
Elan Pharma Int Ltd |
Composiães de nanopartculas com lisozima como um estabilizador superficial
|
|
CN1326569C
(zh)
|
2002-02-26 |
2007-07-18 |
阿斯特拉曾尼卡有限公司 |
含有水溶性纤维素衍生物的iressa药物制剂
|
|
NZ534871A
(en)
|
2002-02-26 |
2007-05-31 |
Astrazeneca Ab |
Novel crystalline forms of the anti-cancer compound ZD1839
|
|
FR2836914B1
(fr)
|
2002-03-11 |
2008-03-14 |
Aventis Pharma Sa |
Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
|
|
MY129850A
(en)
|
2002-04-29 |
2007-05-31 |
Merck Sharp & Dohme |
Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
|
|
US20060177430A1
(en)
|
2002-12-20 |
2006-08-10 |
Chakshu Research Inc |
Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
|
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
|
US20050048112A1
(en)
|
2003-08-28 |
2005-03-03 |
Jorg Breitenbach |
Solid pharmaceutical dosage form
|
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
|
JP4336678B2
(ja)
|
2003-09-04 |
2009-09-30 |
株式会社日立超エル・エス・アイ・システムズ |
半導体装置
|
|
US7642260B2
(en)
|
2003-11-13 |
2010-01-05 |
Abbott Laboratories, Inc. |
Apoptosis promoters
|
|
WO2005049593A2
(en)
|
2003-11-13 |
2005-06-02 |
Abbott Laboratories |
N-acylsulfonamide apoptosis promoters
|
|
US7767684B2
(en)
|
2003-11-13 |
2010-08-03 |
Abbott Laboratories |
Apoptosis promoters
|
|
US8614318B2
(en)
|
2003-11-13 |
2013-12-24 |
Abbvie Inc. |
Apoptosis promoters
|
|
US7973161B2
(en)
|
2003-11-13 |
2011-07-05 |
Abbott Laboratories |
Apoptosis promoters
|
|
US7790190B2
(en)
|
2004-03-20 |
2010-09-07 |
Yasoo Health, Inc. |
Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
|
|
ES2294494T3
(es)
|
2004-04-19 |
2008-04-01 |
Symed Labs Limited |
Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
|
|
US7318503B2
(en)
|
2004-04-26 |
2008-01-15 |
Akebono Corporation (North America) |
Pad retaining clips
|
|
JP2007536299A
(ja)
|
2004-05-04 |
2007-12-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｌｔｂ４アンタゴニトを含有する固形医薬形態
|
|
EP1768967B1
(en)
|
2004-07-20 |
2009-04-22 |
Symed Labs Limited |
Novel intermediates for linezolid and related compounds
|
|
MY191349A
(en)
*
|
2004-08-27 |
2022-06-17 |
Bayer Pharmaceuticals Corp |
New pharmaceutical compositions for the treatment of hyper-proliferative disorders
|
|
CA2578442A1
(en)
|
2004-08-27 |
2006-03-09 |
Bayer Pharmaceuticals Corporation |
Pharmaceutical compositions comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide for the treatment of cancer
|
|
FR2875409B1
(fr)
|
2004-09-17 |
2010-05-07 |
Sanofi Aventis |
Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
|
|
JP2008514702A
(ja)
|
2004-09-29 |
2008-05-08 |
エーエムアール テクノロジー インコーポレイテッド |
新規シクロスポリン類似体およびそれらの薬学的使用
|
|
ES2493466T3
(es)
|
2005-05-12 |
2014-09-11 |
Abbvie Bahamas Ltd. |
Promotores de la apoptosis
|
|
US8624027B2
(en)
|
2005-05-12 |
2014-01-07 |
Abbvie Inc. |
Combination therapy for treating cancer and diagnostic assays for use therein
|
|
AU2006247322A1
(en)
|
2005-05-16 |
2006-11-23 |
Irm Llc |
Pyrrolopyridine derivatives as protein kinase inhibitors
|
|
CN1706371B
(zh)
|
2005-05-27 |
2010-11-10 |
沈阳药科大学 |
一种高效的马蔺子素制剂及其制备方法
|
|
TW200716636A
(en)
|
2005-05-31 |
2007-05-01 |
Speedel Experimenta Ag |
Heterocyclic spiro-compounds
|
|
MY153898A
(en)
|
2005-06-22 |
2015-04-15 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
US7514068B2
(en)
|
2005-09-14 |
2009-04-07 |
Concert Pharmaceuticals Inc. |
Biphenyl-pyrazolecarboxamide compounds
|
|
ATE544444T1
(de)
|
2005-10-11 |
2012-02-15 |
Yissum Res Dev Co |
Zusammensetzungen für die nasale abgabe
|
|
CA2626579A1
(en)
|
2005-10-25 |
2007-05-03 |
Abbott Laboratories |
Formulation comprising a drug of low water solubility and method of use thereof
|
|
US7151188B1
(en)
|
2005-11-16 |
2006-12-19 |
General Electric Company |
Process for the production of mercaptoalkylalkoxysilanes
|
|
WO2007133796A2
(en)
|
2006-05-15 |
2007-11-22 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
|
|
CA2656393A1
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Method of using substituted piperidines that increase p53 activity
|
|
CN101511800B
(zh)
|
2006-07-14 |
2013-02-27 |
坎莫森特里克斯公司 |
三唑基苯基苯磺酰胺
|
|
EP1880715A1
(en)
|
2006-07-19 |
2008-01-23 |
Abbott GmbH & Co. KG |
Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
|
|
US7799790B2
(en)
|
2006-07-20 |
2010-09-21 |
Helm Ag |
Amorphous aripiprazole and process for the preparation thereof
|
|
WO2008021347A2
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Method for making solid dispersions of highly crystalline therapeutic compounds
|
|
MX2009002422A
(es)
|
2006-09-05 |
2009-03-20 |
Abbott Lab |
Inhibidores bcl para tratar exceso de plaquetas.
|
|
US8796267B2
(en)
|
2006-10-23 |
2014-08-05 |
Concert Pharmaceuticals, Inc. |
Oxazolidinone derivatives and methods of use
|
|
WO2008055966A1
(en)
|
2006-11-09 |
2008-05-15 |
Abbott Gmbh & Co. Kg |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
|
WO2008067164A2
(en)
*
|
2006-11-15 |
2008-06-05 |
Abbott Laboratories |
Solid pharmaceutical dosage formulations
|
|
US20080182845A1
(en)
|
2006-11-16 |
2008-07-31 |
Abbott Laboratories |
Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
|
|
MX2009008465A
(es)
|
2007-02-15 |
2009-08-20 |
Hoffmann La Roche |
Nuevas 2-aminooxazolinas como ligandos de taar1.
|
|
RU2351352C2
(ru)
|
2007-04-09 |
2009-04-10 |
Закрытое акционерное общество "Санкт-Петербургский институт фармации" |
Твердая нанокомпозиция для доставки биологически активных веществ
|
|
WO2008124878A1
(en)
|
2007-04-13 |
2008-10-23 |
Cryptopharma Pty Ltd |
Non-steroidal compounds
|
|
US7528131B2
(en)
|
2007-04-19 |
2009-05-05 |
Concert Pharmaceuticals Inc. |
Substituted morpholinyl compounds
|
|
US7531685B2
(en)
|
2007-06-01 |
2009-05-12 |
Protia, Llc |
Deuterium-enriched oxybutynin
|
|
US20090131485A1
(en)
|
2007-09-10 |
2009-05-21 |
Concert Pharmaceuticals, Inc. |
Deuterated pirfenidone
|
|
US20090118238A1
(en)
|
2007-09-17 |
2009-05-07 |
Protia, Llc |
Deuterium-enriched alendronate
|
|
US20090088416A1
(en)
|
2007-09-26 |
2009-04-02 |
Protia, Llc |
Deuterium-enriched lapaquistat
|
|
US20090082471A1
(en)
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched fingolimod
|
|
AU2008307565A1
(en)
|
2007-10-01 |
2009-04-09 |
The Johns Hopkins University |
Methods of treating neurological autoimmune disorders with cyclophosphamide
|
|
WO2009045476A1
(en)
|
2007-10-02 |
2009-04-09 |
Concert Pharmaceuticals, Inc. |
Pyrimidinedione derivatives
|
|
MX2010003642A
(es)
|
2007-10-12 |
2010-08-09 |
Massachusetts Inst Technology |
Nanotecnologia de vacuna.
|
|
EP2212298B1
(en)
|
2007-10-18 |
2013-03-27 |
Concert Pharmaceuticals Inc. |
Deuterated etravirine
|
|
US20090105338A1
(en)
|
2007-10-18 |
2009-04-23 |
Protia, Llc |
Deuterium-enriched gabexate mesylate
|
|
WO2009055006A1
(en)
|
2007-10-26 |
2009-04-30 |
Concert Pharmaceuticals, Inc. |
Deuterated darunavir
|
|
NZ585085A
(en)
|
2007-11-16 |
2012-08-31 |
Abbott Lab |
Method of treating arthritis using arylsulfonamide compounds
|
|
US20090149461A1
(en)
|
2007-12-06 |
2009-06-11 |
Abbott Laboratories |
Method of treating cancer
|
|
ES2579231T3
(es)
|
2008-01-15 |
2016-08-08 |
Abbvie Inc |
Vectores de expresión de mamíferos mejorados y usos de los mismos
|
|
CN101220008B
(zh)
|
2008-01-21 |
2011-04-27 |
中国科学院广州生物医药与健康研究院 |
化合物abt-263的合成方法
|
|
WO2009100176A2
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
|
CN101548960B
(zh)
|
2008-04-01 |
2012-11-07 |
沈阳药科大学 |
高溶出度口服联苯双酯胶囊及其制备方法
|
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
|
EP2346495B2
(en)
|
2008-10-07 |
2023-05-24 |
Kudos Pharmaceuticals Limited |
Pharmaceutical formulation 514
|
|
US20100160322A1
(en)
|
2008-12-04 |
2010-06-24 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
UA108193C2
(uk)
*
|
2008-12-04 |
2015-04-10 |
|
Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
|
|
US8557983B2
(en)
|
2008-12-04 |
2013-10-15 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
NZ614305A
(en)
*
|
2008-12-05 |
2015-03-27 |
Abbvie Inc |
Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
|
US8586754B2
(en)
|
2008-12-05 |
2013-11-19 |
Abbvie Inc. |
BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
|
US8563735B2
(en)
*
|
2008-12-05 |
2013-10-22 |
Abbvie Inc. |
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
|
WO2010077740A2
(en)
|
2008-12-09 |
2010-07-08 |
Cytokine Pharmasciences, Inc. |
Novel antiviral compounds, compositions, and methods of use
|
|
US8959548B2
(en)
*
|
2008-12-22 |
2015-02-17 |
Verizon Patent And Licensing Inc. |
Presenting advertisements with video program descriptions
|
|
WO2010072734A2
(en)
|
2008-12-23 |
2010-07-01 |
The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
|
|
NZ616828A
(en)
*
|
2009-01-19 |
2015-03-27 |
Abbvie Inc |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
RU2538965C2
(ru)
|
2009-01-19 |
2015-01-10 |
Эббви Инк. |
Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
|
|
US8728516B2
(en)
|
2009-04-30 |
2014-05-20 |
Abbvie Inc. |
Stabilized lipid formulation of apoptosis promoter
|
|
US20100280031A1
(en)
|
2009-04-30 |
2010-11-04 |
Paul David |
Lipid formulation of apoptosis promoter
|
|
US20100278921A1
(en)
|
2009-04-30 |
2010-11-04 |
Fischer Cristina M |
Solid oral formulation of abt-263
|
|
US20100297194A1
(en)
|
2009-04-30 |
2010-11-25 |
Nathaniel Catron |
Formulation for oral administration of apoptosis promoter
|
|
US8362013B2
(en)
|
2009-04-30 |
2013-01-29 |
Abbvie Inc. |
Salt of ABT-263 and solid-state forms thereof
|
|
ES2546294T7
(es)
*
|
2009-05-26 |
2024-06-06 |
Abbvie Ireland Unlimited Co |
Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
|
|
US8546399B2
(en)
|
2009-05-26 |
2013-10-01 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
TWI532484B
(zh)
|
2009-06-08 |
2016-05-11 |
艾伯維有限公司 |
包含凋亡促進劑之固態分散劑
|
|
TWI540132B
(zh)
|
2009-06-08 |
2016-07-01 |
亞培公司 |
Ｂｃｌ-２族群抑制劑之口服醫藥劑型
|
|
EP2853531A3
(en)
|
2009-06-11 |
2015-08-12 |
AbbVie Bahamas Ltd. |
Antiviral compounds
|
|
EP2442789A1
(en)
|
2009-06-18 |
2012-04-25 |
Abbott Laboratories |
Stable nanoparticulate drug suspension
|
|
KR20120085781A
(ko)
|
2009-09-20 |
2012-08-01 |
아보트 러보러터리즈 |
Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물
|
|
CN101798292A
(zh)
|
2010-03-29 |
2010-08-11 |
无锡好芳德药业有限公司 |
ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
|
|
TWI520960B
(zh)
|
2010-05-26 |
2016-02-11 |
艾伯維有限公司 |
用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
|
|
KR20180059560A
(ko)
|
2010-10-29 |
2018-06-04 |
애브비 인코포레이티드 |
아폽토시스―유도제를 포함하는 고체 분산체
|
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
|
RU2593231C2
(ru)
|
2010-11-23 |
2016-08-10 |
ЭббВи Айэленд Анлимитед Компани |
Способы лечения с использованием селективных ингибиторов bcl-2
|
|
WO2012071336A1
(en)
|
2010-11-23 |
2012-05-31 |
Abbott Laboratories |
Salts and crystalline forms of an apoptosis-inducing agent
|
|
EP2776603B1
(en)
|
2011-11-11 |
2019-03-06 |
SiO2 Medical Products, Inc. |
PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS
|